ArticleFrontiers in medicine2026
Comparison of the efficacy of low, moderate and standard doses of rituximab in the treatment of membranous nephropathy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab.Oxford medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rituximab (RTX) is recommended as a first-line therapy for membranous nephropathy (MN); however, the efficacy of different dosing regimens remains controversial. This study aimed to evaluate and compare the efficacy of low-dose, moderate- and standard-dose RTX in treating MN. Methods: One hundred patients with MN who received RTX at the Affiliated Hospital of Xuzhou Medical University and Huaihai Hospital of Xuzhou Medical University between May 2021 and December 2024 were included. The patients were divided into three groups: a low-dose group ( Results: After 12 months of treatment, for 24 h-UTP, CD20 Conclusion: Three treatment regimens significantly reduced anti-PLA2R antibody titers and urinary protein levels, while increasing serum albumin, without a significant impact on renal function. The therapeutic efficacy of the three doses was comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.